Developer docs
API playgroundTry for free, no card

Search company profiles

OPM Biosciences

Full company profile

uuid0051rfj

Namestring
OPM Biosciences
Legal namestring
OPM Biosciences Inc.
Websiteurl
opmbio.com
Company typeenum
Private
Founded yearint
2013
Descriptiontext

OPM Biosciences is a privately held life sciences company founded in 2013 and headquartered in Shanghai, China, with U.S. operations in Pleasanton, California. The company develops and manufactures chemically defined cell culture media and reagents used in the production of biologics, with primary product lines centered on CHO and HEK293 cell culture media (under brand families OpmCHO and OpmHEK293) and the CarpTrans transfection reagent, which is backed by an FDA Drug Master File. OPM reports that its products are used in the development of over 390 molecule candidates and serve more than 2,000 customers globally, including over 1,000 biotech, pharmaceutical, and academic research organizations, with claimed performance of 96% average titer improvement and 35%+ cost savings versus prior processes.

The company's media portfolio is built around chemically defined formulations engineered for specific cell lines, manufactured at two Shanghai facilities — Lingang (~6,000 m²) and Ziping (~2,000 m²) — both operating under ISO 9001:2015 and ISO 13485 quality certifications. Manufacturing capacity is extended through affiliated service businesses: contract development and manufacturing (CDMO) services are delivered through a sister company called Sureness with 5,400L of capacity, while preclinical CRO services are channeled through PharmaLegacy. In January 2026, PharmaLegacy was integrated into OPM to create a media-plus-CRDMO platform spanning drug discovery through commercial manufacturing.

OPM's business model combines product sales of cell culture media and reagents with service revenue from CDMO contracts routed through Sureness and preclinical work through PharmaLegacy. Pricing signals include a free sample program targeting evaluation by prospective biopharma customers, indicating a land-and-expand commercialization approach aimed at the long tail of biologic developers. Go-to-market is executed through direct sales in the United States via its Pleasanton office and through the parent organization's reach across Asian and European biopharma customers, with no third-party distribution dependence.

Short descriptiontext

OPM Biosciences is a Shanghai-based, privately held developer and manufacturer of chemically defined cell culture media (CHO and HEK293 series) and transfection reagents, serving over 2,000 biotech, pharmaceutical, and research customers globally with integrated CDMO services.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersShanghai, China
HQ citystring
Shanghai
HQ countrystring
China
HQ regionstring
Asia
Markets served

Serves global market

Offices5 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cell culture media, biologics CDMO services, mammalian cell culture, GMP biomanufacturing, monoclonal antibody production
Industry2 codes
PRIMARYHLAGAHAL
GMP Scale-Up, Tech Transfer & Process Validation (PPQ)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAGAAAB
Preclinical CROs (Discovery/Pharmacology/DMPK)
NAICS code3 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Pharmaceutical Preparation Manufacturing325412
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • Pharmaceutical Preparations2834
Product category
Bioprocessing Cell Culture Media & CDMO Services
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model4 records
1Cell Culture Media Products
TypeOne Time License
Description

Sale of catalog cell culture media products including basal media, feeds, and supplements for CHO and HEK293 cell lines. Products are available in dry powder and liquid formats with GMP-grade and research-grade options.

opmbio.com
2CDMO Services
TypeManaged Services
Description

Comprehensive contract development and manufacturing services including antibody discovery, stable cell line development, cell banking, upstream/downstream process development, formulation development, manufacturing, and QC/product characterization.

opmbio.com
3Custom Media Development Services
TypeProfessional Services
Description

Tailored cell culture media development services with high-throughput screening platform, delivering results within 3-6 months. Includes tech transfer to custom cGMP manufacturing.

opmbio.com
4CRO Services (via PharmaLegacy)
TypeProfessional Services
Description

Preclinical pharmacology, pharmacokinetics, DMPK, and GLP toxicology services through sister company PharmaLegacy.

opmbio.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Supply Chain, Technology or R&D, Infrastructure, Marketing or Sales
Pricing details2 tiers
1Free sample program for new customers
ModelFreemiumBilling cadencePay-as-you-go
Notes

Free samples offered in various sizes and formats to new customers wanting to test products with their process.

opmbio.com
2Cell Culture Media Evaluation Service tiers
ModelOtherBilling cadenceMulti-year contract
Notes

Three service tiers: Tier 1 Rapid Benchmarking, Tier 2 Benchmark & Robustness, Tier 3 Bridge to Optimization. Quote-based pricing.

opmbio.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

OPM Biosciences develops and manufactures chemically defined, animal-origin-free cell culture media, feeds, and supplements for CHO and HEK293 mammalian cell lines used in biologics development and manufacturing. The company also provides integrated CRDMO services spanning antibody discovery, stable cell line development, upstream/downstream process development, formulation, GMP manufacturing, and QC/product characterization, complemented by preclinical CRO services through sister company PharmaLegacy.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • 96% average titer improvement using OPM media and feeds
+5 more records
Product overview1 text field

OPM Biosciences offers an integrated platform combining high-performance cell culture media products with comprehensive CRDMO (Contract Research, Development, and Manufacturing Organization) services. The product portfolio consists of two main cell culture media lines: OPM-CHO products (AltairCHO, SagiCHO, StarCHO, StarCHO Plus, HelixCHO, VegaCHO basal media, paired with DenebCHO, SagiCHO, StarCHO Feed Plus, HelixCHO, VectorCHO feeds and CDFS36/CDFS12 supplements) for Chinese Hamster Ovary cells, and OPM-293 products (OPM-293 CD05, 293F Hi-Exp basal media; OPM-293 ProFeed, 293F Hi-Exp feeds) plus CarpTrans transfection reagent for HEK293 cells. These chemically defined, animal-origin-free media and feeds deliver an average 96% titer improvement. The CRDMO services span the entire biologics development lifecycle through sister company Sureness, including antibody discovery, stable cell line development, cell banking, upstream and downstream process development, formulation development, GMP manufacturing (up to 2000L), and QC/product characterization. An additional CRO service layer through PharmaLegacy (joined January 2026) provides preclinical pharmacology, DMPK, and GLP toxicology, creating a unified Media + CRDMO ecosystem for global biopharma innovation.

Product and service20 records
1AltairCHO Medium
CategoryCHO basal cell culture medium
Description

Chemically defined, animal-origin-free basal medium designed for high-titer monoclonal antibody production in CHO-K1, CHOK1SV GS-KO, CHO-S, and CHO-DXB11 cell lines, sold to biopharmaceutical manufacturers.

2SagiCHO Medium
3StarCHO Medium
4StarCHO Plus Medium
5HelixCHO Medium
6VegaCHO Medium
7DenebCHO Feed
8SagiCHO Feed
9StarCHO Feed Plus
10HelixCHO Feed
11VectorCHO Feed
12CDFS36 Feed Supplement
13CDFS12 Feed Supplement
14OPM-293 CD05 Medium
15293F Hi-Exp Medium
16OPM-293 ProFeed
17293F Hi-Exp Feed
18CarpTrans Transfection Reagent
19CDMO Services for Biologics
20Custom Media Development
Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-01-01
Description

PharmaLegacy, a leading CRO specializing in preclinical pharmacology and efficacy evaluation, joined OPM in January 2026. Founded in 2008, PharmaLegacy has supported 700+ new drug filing projects with expertise in in vitro and in vivo pharmacology, DMPK, GLP toxicology, and Class III medical device evaluation. The partnership creates a unified 'Media + CRDMO' platform integrating best-in-class products and services spanning research, development, manufacturing, and global commercialization.

2Sureness
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Sister company providing integrated CDMO services supporting biologics programs from early development through commercial production. Through Sureness, OPM offers end-to-end biologics CRDMO services.

opmbio.com
Strategic tierMinorTypeGTM or Marketing Partner
Description

Industry organization partnership for connecting with researchers and biotechnology industry stakeholders.

Strategic tierMinorTypeGTM or Marketing Partner
Description

California-based life sciences industry organization partnership.

Strategic tierMinorTypeGTM or Marketing Partner
Description

California-based life sciences industry association partnership.

Strategic tierMinorTypeGTM or Marketing Partner
Description

Massachusetts biotechnology industry organization partnership for connecting with researchers in the biotech hub.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Samsung Biologics is a direct peer offering large-scale mammalian-cell CDMO services from cell line development through commercial manufacturing, serving the same global biopharma customer base as OPM's CDMO business and competing for similar late-stage and commercial contracts.

TypeBroad incumbent
Description

Through the Gibco brand, Thermo Fisher is the broad incumbent in cell culture media — offering the widest catalog of CHO, HEK293, and other mammalian media plus bioproduction services — and serves as the default media supplier against which OPM benchmarks performance and pricing.

TypeDirect peer
Description

Sartorius is a direct peer in cell culture media and bioprocess solutions, providing upstream media, feeds, and bioreactor-integrated workflows for biologics developers — directly competing with OPM's CHO and HEK293 media portfolios and process-development services.

TypeDirect peer
Description

FUJIFILM Irvine Scientific is a direct cell culture media competitor specializing in chemically defined media for CHO, HEK293, and other mammalian cell lines used in vaccine and therapeutic protein manufacturing — overlapping directly with OPM's core product lines.

TypeDirect peer
Description

Lonza is the closest direct peer: a global leader in both mammalian cell culture media products (including the proprietary media franchise acquired through multiple transactions) and full-spectrum biologics CDMO services from cell line development through commercial manufacturing — the exact "Media + CDMO" model OPM is building toward.

TypeDirect peer
Description

AGC Biologics is a direct peer providing mammalian-cell CDMO services spanning cell line development, process development, and GMP manufacturing for antibodies and recombinant proteins — competing with OPM's CDMO operations for similar mid-sized biotech customers.

7Merck KGaA / MilliporeSigma
TypeBroad incumbent
Description

MilliporeSigma is a broad incumbent offering cell culture media, bioprocessing single-use systems, and BioReliance contract testing/development services — overlapping with OPM across both media catalog sales and CRDMO-style offerings.

TypeDirect peer
Description

WuXi Biologics is a global biologics CDMO peer offering end-to-end discovery, development, and GMP manufacturing services — directly comparable to OPM's CDMO/Sureness operations and similarly rooted in China with Western biopharma customers.

TypeDirect peer
Description

Cytiva (formerly GE Healthcare Life Sciences) is a direct competitor in cell culture media, feeds, supplements, and bioprocessing workflows for CHO-based biologics manufacturing, offering overlapping catalog products and process-development services targeted at the same biopharma customers as OPM.

TypeEmerging player
Description

ChemPartner is a relevant comparator as a China-anchored CRO/CDMO providing biologics discovery, CMC, and cell-line services — and notably the prior employer of OPM's founder/CEO Dr. Xiao — making it a closely related emerging peer for talent, customer overlap, and capability benchmarking.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

OPM Biosciences

Bioprocessing Cell Culture Media & CDMO Servicesopmbio.com

OPM Biosciences is a Shanghai-based, privately held developer and manufacturer of chemically defined cell culture media (CHO and HEK293 series) and transfection reagents, serving over 2,000 biotech, pharmaceutical, and research customers globally with integrated CDMO services.

What OPM Biosciences does

OPM Biosciences is a privately held life sciences company founded in 2013 and headquartered in Shanghai, China, with U.S. operations in Pleasanton, California. The company develops and manufactures chemically defined cell culture media and reagents used in the production of biologics, with primary product lines centered on CHO and HEK293 cell culture media (under brand families OpmCHO and OpmHEK293) and the CarpTrans transfection reagent, which is backed by an FDA Drug Master File. OPM reports that its products are used in the development of over 390 molecule candidates and serve more than 2,000 customers globally, including over 1,000 biotech, pharmaceutical, and academic research organizations, with claimed performance of 96% average titer improvement and 35%+ cost savings versus prior processes.

The company's media portfolio is built around chemically defined formulations engineered for specific cell lines, manufactured at two Shanghai facilities — Lingang (~6,000 m²) and Ziping (~2,000 m²) — both operating under ISO 9001:2015 and ISO 13485 quality certifications. Manufacturing capacity is extended through affiliated service businesses: contract development and manufacturing (CDMO) services are delivered through a sister company called Sureness with 5,400L of capacity, while preclinical CRO services are channeled through PharmaLegacy. In January 2026, PharmaLegacy was integrated into OPM to create a media-plus-CRDMO platform spanning drug discovery through commercial manufacturing.

OPM's business model combines product sales of cell culture media and reagents with service revenue from CDMO contracts routed through Sureness and preclinical work through PharmaLegacy. Pricing signals include a free sample program targeting evaluation by prospective biopharma customers, indicating a land-and-expand commercialization approach aimed at the long tail of biologic developers. Go-to-market is executed through direct sales in the United States via its Pleasanton office and through the parent organization's reach across Asian and European biopharma customers, with no third-party distribution dependence.

OPM Biosciences firmographics

Firmographics
Name
OPM Biosciences
Legal name
OPM Biosciences Inc.
Website
https://opmbio.com
Company type
Private
Founded year
2013
Operating status
Operating
Headcount range
11–50 employees
Short description
OPM Biosciences is a Shanghai-based, privately held developer and manufacturer of chemically defined cell culture media (CHO and HEK293 series) and transfection reagents, serving over 2,000 biotech, pharmaceutical, and research customers globally with integrated CDMO services.
Ownership category
akta.pro rank

OPM Biosciences industry classification

Industry
Product category
Bioprocessing Cell Culture Media & CDMO Services
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Services-Commercial Physical & Biological Research (8731), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAGAHAL
GMP Scale-Up, Tech Transfer & Process Validation (PPQ)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAGAAAB
Preclinical CROs (Discovery/Pharmacology/DMPK)

Keywords

  • Cell culture media
  • Biologics CDMO services
  • Mammalian cell culture
  • GMP biomanufacturing
  • Monoclonal antibody production

Where OPM Biosciences is headquartered

Location

Headquarters

HQ city
Shanghai
HQ country
China
HQ region
Asia

Offices5 records

Markets served

OPM Biosciences business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Operations, Supply Chain, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

  1. Cell Culture Media Products: Sale of catalog cell culture media products including basal media, feeds, and supplements for CHO and HEK293 cell lines. Products are available in dry powder and liquid formats with GMP-grade and research-grade options.
  2. CDMO Services: Comprehensive contract development and manufacturing services including antibody discovery, stable cell line development, cell banking, upstream/downstream process development, formulation development, manufacturing, and QC/product characterization.
  3. Custom Media Development Services: Tailored cell culture media development services with high-throughput screening platform, delivering results within 3-6 months. Includes tech transfer to custom cGMP manufacturing.
  4. CRO Services (via PharmaLegacy): Preclinical pharmacology, pharmacokinetics, DMPK, and GLP toxicology services through sister company PharmaLegacy.

Pricing tiers

ModelBillingPrice
FreemiumPay-as-you-goFree sample program for new customers
OtherMulti-year contractCell Culture Media Evaluation Service tiers

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

OPM Biosciences product offering

Product offering

Core offering

OPM Biosciences develops and manufactures chemically defined, animal-origin-free cell culture media, feeds, and supplements for CHO and HEK293 mammalian cell lines used in biologics development and manufacturing. The company also provides integrated CRDMO services spanning antibody discovery, stable cell line development, upstream/downstream process development, formulation, GMP manufacturing, and QC/product characterization, complemented by preclinical CRO services through sister company PharmaLegacy.

Product overview

OPM Biosciences offers an integrated platform combining high-performance cell culture media products with comprehensive CRDMO (Contract Research, Development, and Manufacturing Organization) services. The product portfolio consists of two main cell culture media lines: OPM-CHO products (AltairCHO, SagiCHO, StarCHO, StarCHO Plus, HelixCHO, VegaCHO basal media, paired with DenebCHO, SagiCHO, StarCHO Feed Plus, HelixCHO, VectorCHO feeds and CDFS36/CDFS12 supplements) for Chinese Hamster Ovary cells, and OPM-293 products (OPM-293 CD05, 293F Hi-Exp basal media; OPM-293 ProFeed, 293F Hi-Exp feeds) plus CarpTrans transfection reagent for HEK293 cells. These chemically defined, animal-origin-free media and feeds deliver an average 96% titer improvement. The CRDMO services span the entire biologics development lifecycle through sister company Sureness, including antibody discovery, stable cell line development, cell banking, upstream and downstream process development, formulation development, GMP manufacturing (up to 2000L), and QC/product characterization. An additional CRO service layer through PharmaLegacy (joined January 2026) provides preclinical pharmacology, DMPK, and GLP toxicology, creating a unified Media + CRDMO ecosystem for global biopharma innovation.

Differentiator

Problem solved

Functional benefit

Products and services

  • AltairCHO Medium Chemically defined, animal-origin-free basal medium designed for high-titer monoclonal antibody production in CHO-K1, CHOK1SV GS-KO, CHO-S, and CHO-DXB11 cell lines, sold to biopharmaceutical manufacturers.
  • SagiCHO Medium
  • StarCHO Medium
  • StarCHO Plus Medium
  • HelixCHO Medium
  • VegaCHO Medium
  • DenebCHO Feed
  • SagiCHO Feed
  • StarCHO Feed Plus
  • HelixCHO Feed
  • VectorCHO Feed
  • CDFS36 Feed Supplement
  • CDFS12 Feed Supplement
  • OPM-293 CD05 Medium
  • 293F Hi-Exp Medium
  • OPM-293 ProFeed
  • 293F Hi-Exp Feed
  • CarpTrans Transfection Reagent
  • CDMO Services for Biologics
  • Custom Media Development

Quantifiable outcome

  • 96% average titer improvement using OPM media and feeds
  • +5 more outcomes

Companies that use OPM Biosciences

Customer profile

Named customers3 records

Segments3 records

Ideal customer profiles3 records

OPM Biosciences technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

OPM Biosciences partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core and minor.

  • PharmaLegacycoreStrategic or Co-development Partner · 1 January 2026PharmaLegacy, a leading CRO specializing in preclinical pharmacology and efficacy evaluation, joined OPM in January 2026. Founded in 2008, PharmaLegacy has supported 700+ new drug filing projects with expertise in in vitro and in vivo pharmacology, DMPK, GLP toxicology, and Class III medical device evaluation. The partnership creates a unified 'Media + CRDMO' platform integrating best-in-class products and services spanning research, development, manufacturing, and global commercialization.
  • SurenesscoreStrategic or Co-development PartnerSister company providing integrated CDMO services supporting biologics programs from early development through commercial production. Through Sureness, OPM offers end-to-end biologics CRDMO services.
  • BIOminorGTM or Marketing PartnerIndustry organization partnership for connecting with researchers and biotechnology industry stakeholders.
  • Biocom CaliforniaminorGTM or Marketing PartnerCalifornia-based life sciences industry organization partnership.
  • California Life SciencesminorGTM or Marketing PartnerCalifornia-based life sciences industry association partnership.
  • MassBiominorGTM or Marketing PartnerMassachusetts biotechnology industry organization partnership for connecting with researchers in the biotech hub.

Scale indicators9 records

Recent moves7 records

Expansion highlights6 records

OPM Biosciences competitors and assessment

Company assessment

Direct peers

  • Samsung Biologics: Samsung Biologics is a direct peer offering large-scale mammalian-cell CDMO services from cell line development through commercial manufacturing, serving the same global biopharma customer base as OPM's CDMO business and competing for similar late-stage and commercial contracts.
  • Sartorius AG: Sartorius is a direct peer in cell culture media and bioprocess solutions, providing upstream media, feeds, and bioreactor-integrated workflows for biologics developers — directly competing with OPM's CHO and HEK293 media portfolios and process-development services.
  • FUJIFILM Irvine Scientific: FUJIFILM Irvine Scientific is a direct cell culture media competitor specializing in chemically defined media for CHO, HEK293, and other mammalian cell lines used in vaccine and therapeutic protein manufacturing — overlapping directly with OPM's core product lines.
  • Lonza Group: Lonza is the closest direct peer: a global leader in both mammalian cell culture media products (including the proprietary media franchise acquired through multiple transactions) and full-spectrum biologics CDMO services from cell line development through commercial manufacturing — the exact "Media + CDMO" model OPM is building toward.
  • AGC Biologics: AGC Biologics is a direct peer providing mammalian-cell CDMO services spanning cell line development, process development, and GMP manufacturing for antibodies and recombinant proteins — competing with OPM's CDMO operations for similar mid-sized biotech customers.
  • WuXi Biologics: WuXi Biologics is a global biologics CDMO peer offering end-to-end discovery, development, and GMP manufacturing services — directly comparable to OPM's CDMO/Sureness operations and similarly rooted in China with Western biopharma customers.
  • Cytiva (Danaher): Cytiva (formerly GE Healthcare Life Sciences) is a direct competitor in cell culture media, feeds, supplements, and bioprocessing workflows for CHO-based biologics manufacturing, offering overlapping catalog products and process-development services targeted at the same biopharma customers as OPM.

Broad incumbents

  • Thermo Fisher Scientific (Gibco): Through the Gibco brand, Thermo Fisher is the broad incumbent in cell culture media — offering the widest catalog of CHO, HEK293, and other mammalian media plus bioproduction services — and serves as the default media supplier against which OPM benchmarks performance and pricing.
  • Merck KGaA / MilliporeSigma: MilliporeSigma is a broad incumbent offering cell culture media, bioprocessing single-use systems, and BioReliance contract testing/development services — overlapping with OPM across both media catalog sales and CRDMO-style offerings.

Emerging players

  • ChemPartner: ChemPartner is a relevant comparator as a China-anchored CRO/CDMO providing biologics discovery, CMC, and cell-line services — and notably the prior employer of OPM's founder/CEO Dr. Xiao — making it a closely related emerging peer for talent, customer overlap, and capability benchmarking.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key highlights6 records

Customer concentration

OPM Biosciences social profiles

Digital presence

OPM Biosciences compliance and trust

Trust signal

Compliance3 records

OPM Biosciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

OPM Biosciences leadership team

Management profile

Number of profiles

Profiles2 records

OPM Biosciences funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

OPM Biosciences M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about OPM Biosciences

What does OPM Biosciences do?

OPM Biosciences develops and manufactures chemically defined, animal-origin-free cell culture media, feeds, and supplements for CHO and HEK293 mammalian cell lines used in biologics development and manufacturing. The company also provides integrated CRDMO services spanning antibody discovery, stable cell line development, upstream/downstream process development, formulation, GMP manufacturing, and QC/product characterization, complemented by preclinical CRO services through sister company PharmaLegacy.

Is OPM Biosciences a public or private company?

OPM Biosciences is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was OPM Biosciences founded?

OPM Biosciences was founded in 2013. It employs 11 to 50 people.

Where is OPM Biosciences based?

OPM Biosciences is headquartered in Shanghai, China, in the Asia region.

How does OPM Biosciences make money?

Four revenue lines are on record. Cell Culture Media Products are the primary driver. The others are CDMO Services, custom Media Development Services and CRO Services (via PharmaLegacy).

Who are OPM Biosciences's main competitors?

Direct peers on record are Samsung Biologics, Sartorius AG, FUJIFILM Irvine Scientific, Lonza Group, AGC Biologics, WuXi Biologics and Cytiva (Danaher). Broad incumbents are Thermo Fisher Scientific (Gibco) and Merck KGaA / MilliporeSigma. ChemPartner is listed as an emerging player.

Does OPM Biosciences have an API?

No public API is recorded for OPM Biosciences.

What industry is OPM Biosciences in?

OPM Biosciences's product category is Bioprocessing Cell Culture Media & CDMO Services. Its primary akta.pro industry code is HLAGAHAL, GMP Scale-Up, Tech Transfer & Process Validation (PPQ), with a secondary code of HLAGAAAB, Preclinical CROs (Discovery/Pharmacology/DMPK). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals